Literature DB >> 22365841

Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine.

Masato Kono1, Yutaro Nakamura, Takafumi Suda, Masato Uchijima, Kunio Tsujimura, Toshi Nagata, Adam S Giermasz, Pawel Kalinski, Hirotoshi Nakamura, Kingo Chida.   

Abstract

The development of effective vaccine strategies for intracellular bacteria, including tuberculosis, is one of the major frontiers of medical research. Our previous studies showed that dendritic cell (DC) vaccine is a promising approach for eliciting protective immunity against intracellular bacteria. However, it has been reported that standard fully mature DCs show reduced ability to produce IL-12p70 upon subsequent interaction with antigen (Ag)-specific T cells, limiting their in vivo performance for vaccines. Recently, we found that such "DC exhaustion" could be prevented by the presence of IL-4 and IFN-γ during the maturation of mouse DCs (type-1 polarization), resulting in improved induction of anti-tumor immunity in cancer. Here we show that such type-1 polarized DCs promote dramatic enhancement of protective immunity against an intracellular bacterium, Listeria monocytogenes. Murine bone marrow-derived DCs were cultured and matured with LPS, IL-4 and IFN-γ (type-1 polarized DCs), and with LPS alone (non-polarized DCs). DCs were loaded with listeriolysin O (LLO) 91-99, H2-K(d)-restricted epitope of L. monocytogenes, and were injected into naïve BALB/c mice intravenously. Type-1 polarized DCs produced significantly higher levels of IL-12p70 than non-polarized DCs in vitro, and this vaccine strongly enhanced LLO 91-99-specific CD8(+) T cells exhibiting epitope-specific cytotoxic activity and IFN-γ production, leading to significant induction of protective immunity against L. monocytogenes. Type-1 polarized DCs are potential candidates for enhancing protective immunity in the design of effective vaccination strategies against intracellular bacteria. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365841     DOI: 10.1016/j.vaccine.2012.02.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Advances in the study of HLA-restricted epitope vaccines.

Authors:  Lingxiao Zhao; Min Zhang; Hua Cong
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 2.  Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

Authors:  Lucy M De La Cruz; Nadia F Nocera; Brian J Czerniecki
Journal:  Immunotherapy       Date:  2016-10       Impact factor: 4.196

3.  Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor β.

Authors:  Vanina A Alamino; Iván D Mascanfroni; María M Montesinos; Nicolás Gigena; Ana C Donadio; Ada G Blidner; Sonia I Milotich; Sheue-Yann Cheng; Ana M Masini-Repiso; Gabriel A Rabinovich; Claudia G Pellizas
Journal:  Cancer Res       Date:  2015-02-11       Impact factor: 12.701

4.  The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells.

Authors:  Xin Wan; Ci Cheng; Zhe Lin; Runqiu Jiang; Wei Zhao; Xin Yan; Junwei Tang; Kun Yao; Beicheng Sun; Yun Chen
Journal:  Oncotarget       Date:  2015-04-20

5.  Cellular vaccines in listeriosis: role of the Listeria antigen GAPDH.

Authors:  Ricardo Calderón-González; Elisabet Frande-Cabanes; Lucía Bronchalo-Vicente; M Jesús Lecea-Cuello; Eduardo Pareja; Alexandre Bosch-Martínez; Mónica L Fanarraga; Sonsoles Yañez-Díaz; Eugenio Carrasco-Marín; Carmen Alvarez-Domínguez
Journal:  Front Cell Infect Microbiol       Date:  2014-02-21       Impact factor: 5.293

6.  A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis.

Authors:  Yuelan Yin; Kai Lian; Dan Zhao; Chengwu Tao; Xiang Chen; Weijun Tan; Xiaobo Wang; Zhengzhong Xu; Maozhi Hu; Yan Rao; Xiaohui Zhou; Zhiming Pan; Xiaoming Zhang; Xin'an Jiao
Journal:  Front Cell Infect Microbiol       Date:  2017-09-28       Impact factor: 5.293

7.  Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.

Authors:  Xuan Wang; Fang-Cheng Zhang; Hong-Yang Zhao; Xiao-Ling Lu; Yun Sun; Zhi-Yong Xiong; Xiao-Bing Jiang
Journal:  Tumour Biol       Date:  2014-05-10

8.  A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes.

Authors:  Lucia Bronchalo-Vicente; Estela Rodriguez-Del Rio; Javier Freire; Ricardo Calderon-Gonzalez; Elisabet Frande-Cabanes; Jose Javier Gomez-Roman; Hector Fernández-Llaca; Sonsoles Yañez-Diaz; Carmen Alvarez-Dominguez
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

9.  Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma.

Authors:  Ricardo Calderon-Gonzalez; Lucia Bronchalo-Vicente; Javier Freire; Elisabet Frande-Cabanes; Lidia Alaez-Alvarez; Javier Gomez-Roman; Sonsóles Yañez-Diaz; Carmen Alvarez-Dominguez
Journal:  Oncotarget       Date:  2016-03-29

10.  Novel nanoparticle vaccines for Listeriosis.

Authors:  Ricardo Calderon-Gonzalez; Marco Marradi; Isabel Garcia; Nikolai Petrovsky; Carmen Alvarez-Dominguez
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.